Characterization of ACE Inhibitors and ATR Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model

Overview

Journal Life (Basel)

Specialty Biology

Date 2021 Aug 27

PMID 34440554

Citations 8

Authors

Philipp Reus

Ann-Kathrin Schneider

Thomas Ulshofer

Marina Henke

Denisa Bojkova

Jindrich Cinatl

Sandra Ciesek

Gerd Geisslinger

Volker Laux

Mira Grattinger

Philip Gribbon

Susanne Schiffmann

Affiliations

Soon will be listed here.

Abstract

Methods: We have investigated the influence of the ACE inhibitors (lisinopril, captopril) and the AT antagonists (telmisartan, olmesartan) on the level of ACE2 mRNA and protein expression as well as their influence on the cytopathic effect of SARS-CoV-2 and on the cell barrier integrity in a Caco-2 cell model.

Results: The drugs revealed no effect on ACE2 mRNA and protein expression. ACE inhibitors and ATR antagonist olmesartan did not influence the infection rate of SARS-CoV-2 and were unable to prevent the SARS-CoV-2-induced cell barrier disturbance. A concentration of 25 µg/mL telmisartan significantly reduced the virus replication rate.

Conclusion: ACE inhibitors and ATR antagonist showed neither beneficial nor detrimental effects on SARS-CoV-2-infection and cell barrier integrity in vitro at pharmacologically relevant concentrations.

Citing Articles

Biophysical Analysis of Potential Inhibitors of SARS-CoV-2 Cell Recognition and Their Effect on Viral Dynamics in Different Cell Types: A Computational Prediction from In Vitro Experimental Data.

Gonzalez-Paz L, Lossada C, Hurtado-Leon M, Vera-Villalobos J, Paz J, Marrero-Ponce Y ACS Omega. 2024; 9(8):8923-8939.

PMID: 38434903 PMC: 10905729. DOI: 10.1021/acsomega.3c06968.

Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant.

Mulgaonkar N, Wang H, Zhang J, Roundy C, Tang W, Chaki S Pharmaceutics. 2023; 15(7).

PMID: 37514075 PMC: 10385313. DOI: 10.3390/pharmaceutics15071891.

Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice.

Thieulent C, Dittmar W, Balasuriya U, Crossland N, Wen X, Richt J mSphere. 2023; 8(1):e0055822.

PMID: 36728430 PMC: 9942576. DOI: 10.1128/msphere.00558-22.

Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections.

Chen D, Yun X, Lee D, DiCostanzo J, Donini O, Shikuma C Mol Pharm. 2022; 20(1):750-757.

PMID: 36448927 PMC: 9718101. DOI: 10.1021/acs.molpharmaceut.2c00448.

The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19.

Najafi N, Davoudi A, Izadyar H, Alishahi A, Mokhtariani A, Soleimanpourian B Ir J Med Sci. 2022; 192(3):1517-1523.

PMID: 35854192 PMC: 9296362. DOI: 10.1007/s11845-022-03096-6.

References

Pedrosa M, Valenzuela R, Garrido-Gil P, Labandeira C, Navarro G, Franco R . Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci (Lond). 2021; 135(3):465-481. PMC: 7851407. DOI: 10.1042/CS20201511. View

Lubel J, Herath C, Velkoska E, Casley D, Burrell L, Angus P . Angiotensin converting enzyme 2 (ACE2) activity in fetal calf serum: implications for cell culture research. Cytotechnology. 2009; 58(3):119-26. PMC: 2652558. DOI: 10.1007/s10616-009-9185-0. View

Richardson S, Hirsch J, Narasimhan M, Crawford J, McGinn T, Davidson K . Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020; 323(20):2052-2059. PMC: 7177629. DOI: 10.1001/jama.2020.6775. View

Wildhaber B, Yang H, Haxhija E, Spencer A, Teitelbaum D . Intestinal intraepithelial lymphocyte derived angiotensin converting enzyme modulates epithelial cell apoptosis. Apoptosis. 2005; 10(6):1305-15. PMC: 1351359. DOI: 10.1007/s10495-005-2138-y. View

McIntyre M, Caffe S, Michalak R, Reid J . Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther. 1997; 74(2):181-94. DOI: 10.1016/s0163-7258(97)82002-5. View

Howell S, Brewis I, Hooper N, Kenny A, Turner A . Mosaic expression of membrane peptidases by confluent cultures of Caco-2 cells. FEBS Lett. 1993; 317(1-2):109-12. DOI: 10.1016/0014-5793(93)81502-q. View

Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A . Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020; 117(21):11727-11734. PMC: 7260975. DOI: 10.1073/pnas.2003138117. View

van Griensven J, Schoemaker R, Cohen A, Luus H, Seibert-Grafe M, Rothig H . Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. Eur J Clin Pharmacol. 1995; 47(6):513-8. DOI: 10.1007/BF00193704. View

Richer C, Giroux B, Plouin P, Maarek B, Giudicelli J . Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol. 1984; 17(3):243-50. PMC: 1463370. DOI: 10.1111/j.1365-2125.1984.tb02338.x. View

10.

Cho D . Telmisartan Inhibits Nitric Oxide Production and Vessel Relaxation via Protein Phosphatase 2A-mediated Endothelial NO Synthase-Ser Dephosphorylation. J Korean Med Sci. 2019; 34(42):e266. PMC: 6823522. DOI: 10.3346/jkms.2019.34.e266. View

11.

Suwannasual U, Lucero J, Davis G, McDonald J, Lund A . Mixed Vehicle Emissions Induces Angiotensin II and Cerebral Microvascular Angiotensin Receptor Expression in C57Bl/6 Mice and Promotes Alterations in Integrity in a Blood-Brain Barrier Coculture Model. Toxicol Sci. 2019; 170(2):525-535. PMC: 6657584. DOI: 10.1093/toxsci/kfz121. View

12.

Laeis P, Puchler K, Kirch W . The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001; 19(1):S21-32. DOI: 10.1097/00004872-200106001-00004. View

13.

Lo M, Goldberg M, McCrea J, Lu H, Furtek C, Bjornsson T . Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995; 58(6):641-9. DOI: 10.1016/0009-9236(95)90020-9. View

14.

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

15.

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. PMC: 7136855. DOI: 10.1001/jama.2020.5394. View

16.

Yokoyama S, Kawai T, Yamamoto K, Yibin H, Yamamoto H, Kakino A . RAGE ligands stimulate angiotensin II type I receptor (AT1) via RAGE/AT1 complex on the cell membrane. Sci Rep. 2021; 11(1):5759. PMC: 7952713. DOI: 10.1038/s41598-021-85312-4. View

17.

Lemarie C, Schiffrin E . The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2009; 11(1):19-31. DOI: 10.1177/1470320309347785. View

18.

James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20. DOI: 10.1001/jama.2013.284427. View

19.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

20.

Rossi L, Malagoli A, Biagi A, Zanni A, Sticozzi C, Comastri G . Renin-angiotensin system inhibitors and mortality in patients with COVID-19. Infection. 2020; 49(2):287-294. PMC: 7680554. DOI: 10.1007/s15010-020-01550-0. View